But a challenge to an Orange Book patent, should a brand-name manufacturer decide to fight in court, also delays a generic’s approval for 30 months. The FTC says that drugmakers needlessly list ...
The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk patents," which it contends are ploys intended ...
After the FTC’s November action, several manufacturers de-listed patents and three top drugmakers announced they would cap inhaler out-of-pocket costs at $35. “By filing bogus patent listings, pharma ...
Regulators are focusing on the Food and Drug Administration’s Orange Book, which compiles approved drugs along with patent listings. Altogether, the FTC sent letters to 10 companies, alleging ...
The FTC argues those patents for altogether 20 brand-name products are “junk” listings that could be used by pharma companies to stymie competition and inflate drug prices. AstraZeneca ...
“By filing bogus patent listings, pharma companies block competition and inflate the cost of prescription drugs, forcing Americans to pay sky-high prices for medicines they rely on,” FTC Chair Lina ...
The FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk, AstraZeneca, GlaxoSmithKline and Teva—disputing more than 300 “junk” patent listings across 20 different ...
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining ... they rely on,” FTC Chair Lina Khan ...